Announcements
- Kiadis employee options committed under the Sanofi Offer
- Kiadis Pharma announces annual results for the year ended December 31, 2020
- Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
- Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
- Sanofi launches recommended cash offer for all shares in Kiadis
- Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Kiadis draws €20 million from bridge loan with Sanofi
- Sanofi and Kiadis satisfy competition condition related to the tender offer
- Kiadis issues “holdback” shares to former Cytosen shareholders
More ▼
Key statistics
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 6.55 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.89m |
Free float | 41.81m |
P/E (TTM) | -- |
Market cap | 232.49m EUR |
EPS (TTM) | -2.14 EUR |
Data delayed at least 15 minutes.
More ▼